Patents by Inventor Rich B. Meyer, Jr.

Rich B. Meyer, Jr. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8465921
    Abstract: Conjugates between a minor groove binding molecule, such as the trimer of 1,2-dihydro-(3H)-pyrrolo[3,2-e]indole-7-carboxylate (CDPI3), and an oligonucleotide form unusually stable hybrids with complementary target sequences, in which the tethered CDPI3 group resides in the minor groove of the duplex. These conjugates can be used as probes and primers. Due to their unusually high binding affinity, conjugates as short as 8-mers can be used as amplification primers with high specificity and efficiency. MGB conjugation also increases the discriminatory power of short oligonucleotides, providing enhanced detection of nucleotide sequence mismatches by short oligonucleotides.
    Type: Grant
    Filed: August 31, 2010
    Date of Patent: June 18, 2013
    Assignee: Elitech Holding B.V.
    Inventors: Joel Hedgpeth, Irina A. Afonina, Igor V. Kutyavin, Eugeny A. Lukhtanov, Evgeniy S. Belousov, Rich B. Meyer, Jr.
  • Publication number: 20110275070
    Abstract: Conjugates between a minor groove binding molecule, such as the trimer of 1,2-dihydro-(3H)-pyrrolo[3,2-e]indole-7-carboxylate (CDPI3), and an oligonucleotide form unusually stable hybrids with complementary target sequences, in which the tethered CDPI3 group resides in the minor groove of the duplex. These conjugates can be used as probes and primers. Due to their unusually high binding affinity, conjugates as short as 8-mers can be used as amplification primers with high specificity and efficiency. MGB conjugation also increases the discriminatory power of short oligonucleotides, providing enhanced detection of nucleotide sequence mismatches by short oligonucleotides.
    Type: Application
    Filed: August 31, 2010
    Publication date: November 10, 2011
    Inventors: Joel Hedgpeth, Irina A. Afonina, Igor V. Kutyavin, Eugeny A. Lukhtanov, Evgeniy S. Belousov, Rich B. Meyer, JR.
  • Patent number: 7794945
    Abstract: Conjugates between a minor groove binding molecule, such as the trimer of 1,2-dihydro-(3H)-pyrrolo[3,2-e]indole-7-carboxylate (CDPI3), and an oligonucleotide form unusually stable hybrids with complementary target sequences, in which the tethered CDPI3 group resides in the minor groove of the duplex. These conjugates can be used as probes and primers. Due to their unusually high binding affinity, conjugates as short as 8-mers can be used as amplification primers with high specificity and efficiency. MGB conjugation also increases the discriminatory power of short oligonucleotides, providing enhanced detection of nucleotide sequence mismatches by short oligonucleotides.
    Type: Grant
    Filed: July 14, 2008
    Date of Patent: September 14, 2010
    Assignee: Elitech Holding B.V.
    Inventors: Joel Hedgpeth, Irina A. Afonina, Igor V. Kutyavin, Eugeny A. Lukhtanov, Evgeniy S. Belousov, Rich B. Meyer, Jr.
  • Publication number: 20100228017
    Abstract: Oligonucleotides in which one or more purine residues are substituted by pyrazolo[3,4-d]pyrimidines exhibit improved hybridization properties. Oligonucleotides containing pyrazolo[3,4-d]pyrimidine base analogues have higher melting temperatures than unsubstituted oligonucleotides of identical sequence. Thus, in assays involving hybridization of an oligonucleotide probe to a target polynucleotide sequence, higher signals are obtained. In addition, mismatch discrimination is enhanced when pyrazolo[3,4-d]pyrimidine-containing oligonucleotides are used as hybridization probes, making them useful as probes and primers for hybridization, amplification and sequencing procedures, particularly those in which single- or multiple-nucleotide mismatch discrimination is required.
    Type: Application
    Filed: January 7, 2008
    Publication date: September 9, 2010
    Inventors: Rich B. Meyer, JR., Irina A. Afonina, Igor V. Kutyavin
  • Patent number: 7556923
    Abstract: Conjugates between a minor groove binding molecule, such as the trimer of 1,2-dihydro-(3H)-pyrrolo[3,2-e]indole-7-carboxylate (CDPI3), and an oligonucleotide form unusually stable hybrids with complementary target sequences, in which the tethered CDPI3 group resides in the minor groove of the duplex. These conjugates can be used as probes and primers. Due to their unusually high binding affinity, conjugates as short as 8-mers can be used as amplification primers with high specificity and efficiency. MGB conjugation also increases the discriminatory power of short oligonucleotides, providing enhanced detection of nucleotide sequence mismatches by short oligonucleotides.
    Type: Grant
    Filed: April 6, 2007
    Date of Patent: July 7, 2009
    Assignee: Epoch Biosciences, Inc.
    Inventors: Joel Hedgpeth, Irina A. Afonina, Igor V. Kutyavin, Eugeny A. Lukhtanov, Evgeniy S. Belousov, Rich B. Meyer, Jr.
  • Publication number: 20090048427
    Abstract: Conjugates between a minor groove binding molecule, such as the trimer of 1,2-dihydro-(3H)-pyrrolo[3,2-e]indole-7-carboxylate (CDPI3), and an oligonucleotide form unusually stable hybrids with complementary target sequences, in which the tethered CDPI3 group resides in the minor groove of the duplex. These conjugates can be used as probes and primers. Due to their unusually high binding affinity, conjugates as short as 8-mers can be used as amplification primers with high specificity and efficiency. MGB conjugation also increases the discriminatory power of short oligonucleotides, providing enhanced detection of nucleotide sequence mismatches by short oligonucleotides.
    Type: Application
    Filed: July 14, 2008
    Publication date: February 19, 2009
    Applicant: EPOCH BIOSCIENCES, INC.
    Inventors: JOEL HEDGPETH, IRINA A. AFONINA, IGOR V. KUTYAVIN, EUGENY A. LUKHTANOV, EVGENIY S. BELOUSOV, RICH B. MEYER, JR.
  • Patent number: 6884584
    Abstract: Conjugates between a minor groove binding molecule, such as the trimer of 1,2-dihydro-(3H)-pyrrolo[3,2-e]indole-7-carboxylate (CDPI3), and an oligonucleotide form unusually stable hybrids with complementary target sequences, in which the tethered CDPI3 group resides in the minor groove of the duplex. These conjugates can be used as probes and primers. Due to their unusually high binding affinity, conjugates as short as 8-mers can be used as amplification primers with high specificity and efficiency. MGB conjugation also increases the discriminatory power of short oligonucleotides, providing enhanced detection of nucleotide sequence mismatches by short oligonucleotides.
    Type: Grant
    Filed: April 22, 2002
    Date of Patent: April 26, 2005
    Assignee: Epoch Biosciences, Inc.
    Inventors: Joel Hedgpeth, Irina A. Afonina, Igor V. Kutyavin, Eugeny A. Lukhtanov, Evgeniy S. Belousov, Rich B. Meyer, Jr.
  • Patent number: 6492346
    Abstract: Conjugates between a minor groove binding molecule, such as the trimer of 1,2-dihydro-(3H)-pyrrolo[3,2-e]indole-7-carboxylate (CDPI3), and an oligonucleotide form unusually stable hybrids with complementary target sequences, in which the tethered CDPI3 group resides in the minor groove of the duplex. These conjugates can be used as probes and primers. Due to their unusually high binding affinity, conjugates as short as 8-mers can be used as amplification primers with high specificity and efficiency. MGB conjugation also increases the discriminatory power of short oligonucleotides, providing enhanced detection of nucleotide sequence mismatches by short oligonucleotides.
    Type: Grant
    Filed: August 16, 2000
    Date of Patent: December 10, 2002
    Assignee: Epoch Pharmaceuticals, Inc.
    Inventors: Joel Hedgpeth, Irina A. Afonina, Igor V. Kutyavin, Eugeny A. Lukhtanov, Evgeniy S. Belousov, Rich B. Meyer, Jr.
  • Patent number: 6485906
    Abstract: Oligonucleotides in which one or more purine residues are substituted by pyrazolo[3,4-d]pyrimidines exhibit improved hybridization properties. Oligonucleotides containing pyrazolo[3,4-d]pyrimidine base analogues have higher melting temperatures than unsubstituted oligonucleotides of identical sequence. Thus, in assays involving hybridization of an oligonucleotide probe to a target polynucleotide sequence, higher signals are obtained. In addition, mismatch discrimination is enhanced when pyrazolo[3,4-d]pyrimidine-containing oligonucleotides are used as hybridization probes, making them useful as probes and primers for hybridization, amplification and sequencing procedures, particularly those in which single- or multiple-nucleotide mismatch discrimination is required.
    Type: Grant
    Filed: November 1, 1999
    Date of Patent: November 26, 2002
    Assignee: Epoch Pharmaceuticals, Inc.
    Inventors: Rich B. Meyer, Jr., Irina A. Afonina, Igor V. Kutyavin
  • Patent number: 6486308
    Abstract: Minor groove binding molecules are covalently bound to oligonucleotides which in their base sequence are complementary to a target sequence of single stranded or double stranded DNA, RNA or hybrids thereof. The covalently bound oligonucleotide minor groove binder conjugates strogly bind to the target sequence of the complementary strand.
    Type: Grant
    Filed: December 18, 2000
    Date of Patent: November 26, 2002
    Assignee: Epoch Biosciences, Inc.
    Inventors: Igor V. Kutyavin, Eugeny A. Lukhtanov, Howard B. Gamper, Rich B. Meyer, Jr.
  • Patent number: 6426408
    Abstract: Minor groove binding molecules are covalently bound to oligonucleotides which in their base sequence are complementary to a target sequence of single stranded or double stranded DNA, RNA or hybrids thereof. The covalently bound oligonucleotide minor groove binder conjugates strogly bind to the target sequence of the complementary strand.
    Type: Grant
    Filed: February 18, 2000
    Date of Patent: July 30, 2002
    Assignee: Epoch Biosciences, Inc.
    Inventors: Igor V. Kutyavin, Eugeny A. Lukhtanov, Howard B. Gamper, Rich B. Meyer, Jr.
  • Patent number: 6312925
    Abstract: Methods and compositions for efficient targeting and modification of target sequences in duplex DNA are provided, utilizing oligonucleotides or oligonucleotide compositions containing two domains. The first domain comprises an entity capable of recognizing a double-stranded DNA sequence. This can be a protein, peptide, antibiotic, minor groove binding agent or a nucleotide sequence capable of triplex formation The second domain, which is covalently joined to the first, is capable of recognizing a single-stranded DNA sequence. This second domain will most often be complementary, in the Watson-Crick sense, to a target sequence in the double-stranded nucleic acid. The second domain can optionally carry one or more modifying groups, capable of causing a mutation, a pre-mutagenic lesion, or some other type of heritable change in the target sequence.
    Type: Grant
    Filed: May 7, 1998
    Date of Patent: November 6, 2001
    Assignee: Epoch Pharmaceuticals, Inc.
    Inventors: Rich B. Meyer, Jr., Howard B. Gamper, Jr.
  • Patent number: 6312953
    Abstract: Chemically modified oligonucleotides (ODNS) are complementary, either in the sense of the classic “four letter code” recognition motif, or in the sense required for triple strand formation based on the more limited “two letter code recognition motif”, to a target sequence of double stranded DNA of an invading cell, organism or pathogen, such as a virus, fungus, parasite, bacterium, malignant cell, or any duplex DNA which is desired to be broken into segments for the purpose of “mapping”. The ODNs have cross-linking agents covalently attached at least to two different sites of the ODN. Alternatively, the cross-linking agent which is attached to one site on the ODN has two cross-linking functionalities, and therefore in effect comprises two cross-linking agents.
    Type: Grant
    Filed: June 27, 1994
    Date of Patent: November 6, 2001
    Assignee: Epoch Pharmaceuticals, Inc.
    Inventors: Rich B. Meyer, Jr., Howard B. Gamper, Igor V. Kutyavin, Alexander A. Gall
  • Patent number: 6312894
    Abstract: Conjugates between a minor groove binding molecule, such as the trimer of 1,2-dihydro-(3H)-pyrrolo[3,2-e]indole-7-carboxylate (CDPI3), and an oligonucleotide form unusually stable hybrids with complementary target sequences, in which the tethered CDPI3 group resides in the minor groove of the duplex. These conjugates can be used as probes and primers. Due to their unusually high binding affinity, conjugates as short as 8-mers can be used as amplification primers with high specificity and efficiency. MGB conjugation also increases the discriminatory power of short oligonucleotides, providing enhanced detection of nucleotide sequence mismatches by short oligonucleotides.
    Type: Grant
    Filed: April 3, 1998
    Date of Patent: November 6, 2001
    Assignee: Epoch Pharmaceuticals, Inc.
    Inventors: Joel Hedgpeth, Irina A. Afonina, Igor V. Kutyavin, Eugeny A. Lukhtanov, Evgeniy S. Belousov, Rich B. Meyer, Jr.
  • Patent number: 6136601
    Abstract: A method for introducing a site-specific mutation into a target polynucleotide sequence is presented. The method involves the use of an oligonucleotide capable of binding to the target sequence, either by triplex formation (mediated by Hoogsteen, reverse Hoogsteen or equivalent base pairing) or by Watson/Crick base pairing (in the presence of a recombinase enzyme). The oligonucleotide of the invention is modified by the covalent attachment of one or more electrophilic groups. When a modified oligonucleotide is bound to its target sequence, the electrophilic group is able to interact with a nearby nucleotide in the target sequence, causing a modification to the nucleotide that results in a change in nucleotide sequence. Compositions used in the practice of the method are also disclosed.
    Type: Grant
    Filed: March 26, 1997
    Date of Patent: October 24, 2000
    Assignee: Epoch Pharmaceuticals, Inc.
    Inventors: Rich B. Meyer, Jr., Howard B. Gamper, Igor V. Kutyavin, Alexander A. Gall
  • Patent number: 6127121
    Abstract: Oligonucleotides in which one or more purine residues are substituted by pyrazolo[3,4-d]pyrimidines exhibit improved hybridization properties. Oligonucleotides containing pyrazolo[3,4-d]pyrimidine base analogues have higher melting temperatures than unsubstituted oligonucleotides of identical sequence. Thus, in assays involving hybridization of an oligonucleotide probe to a target polynucleotide sequence, higher signals are obtained. In addition, mismatch discrimination is enhanced when pyrazolo[3,4-d]pyrimidine-containing oligonucleotides are used as hybridization probes, making them useful as probes and primers for hybridization, amplification and sequencing procedures, particularly those in which single- or multiple-nucleotide mismatch discrimination is required.
    Type: Grant
    Filed: April 3, 1998
    Date of Patent: October 3, 2000
    Assignee: Epoch Pharmaceuticals, Inc.
    Inventors: Rich B. Meyer, Jr., Irina A. Afonina, Igor V. Kutyavin
  • Patent number: 6084102
    Abstract: Minor groove binding molecules are covalently bound to oligonucleotides which in their base sequence are complementary to a target sequence of single stranded or double stranded DNA, RNA or hybrids thereof. The covalently bound oligonucleotide minor groove binder conjugates strongly bind to the target sequence of the complementary strand.
    Type: Grant
    Filed: August 27, 1998
    Date of Patent: July 4, 2000
    Assignee: Epoch Pharmaceuticals, Inc.
    Inventors: Igor V. Kutyavin, Eugeny A. Lukhtanov, Howard B. Gamper, Rich B. Meyer, Jr.
  • Patent number: 6072046
    Abstract: Diaziridinyl-aryl and bis-[di(chloroethyl)amino]-aryl oligonucleotide conjugates have a sequence that is complementary in the triplex forming sense to a target sequence in duplex nucleic acid. The diaziridinyl-aryl and bis-[di(chloroethyl)amino]-aryl oligonucleotide conjugates effectively cross-link with both strands of the targeted duplex nucleic acid.
    Type: Grant
    Filed: August 26, 1998
    Date of Patent: June 6, 2000
    Assignee: Epoch Pharmaceuticals, Inc.
    Inventors: Michael W. Reed, Igor V. Kutyavin, Eugeny A. Lukhtanov, J. Ansel Wald, Rich B. Meyer, Jr.
  • Patent number: 5935830
    Abstract: A method for introducing a site-specific mutation into a target polynucleotide sequence is presented. The method involves the use of an oligonucleotide capable of binding to the target sequence, either by triplex formation (mediated by Hoogsteen, reverse Hoogsteen or equivalent base pairing) or by Watson/Crick base pairing (in the presence of a recombinase enzyme). The oligonucleotide of the invention is modified by the covalent attachment of one or more electrophilic groups. When a modified oligonucleotide is bound to its target sequence, the electrophilic group is able to interact with a nearby nucleotide in the target sequence, causing a modification to the nucleotide that results in a change in nucleotide sequence. Compositions used in the practice of the method are also disclosed.
    Type: Grant
    Filed: March 26, 1997
    Date of Patent: August 10, 1999
    Assignee: Epoch Pharmaceuticals, Inc.
    Inventors: Rich B. Meyer, Jr., Howard B. Gamper, Igor V. Kutyavin, Alexander A. Gall
  • Patent number: 5912340
    Abstract: In a matched pair of oligonucleotides (ODNS) each member of the pair is complementary or substantially complementary in the Watson Crick sense to a target sequence of duplex nucleic acid where the two strands of the target sequence are themselves complementary to one another. The ODNs include modified bases of such nature that the modified base forms a stable hydrogen bonded base pair with the natural partner base, but does not form a stable hydrogen bonded base pair with its modified partner. This is accomplished when in a hybridized structure the modified base is capable of forming two or more hydrogen bonds with its natural complementary base, but only one hydrogen bond with its modified partner. Due to the lack of stable hydrogen bonding with each other, the matched pair of oligonucleotides have a melting temperature under physiological or substantially physiological conditions of approximately 40.degree. C. or less.
    Type: Grant
    Filed: October 4, 1995
    Date of Patent: June 15, 1999
    Assignee: Epoch Pharmaceuticals, Inc.
    Inventors: Igor V. Kutyavin, Jinsuk Woo, Eugeny A. Lukhtanov, Rich B. Meyer, Jr., Howard B. Gamper